Powder: -20°C for 3 years
In solvent: -80°C for 2 years
PF-05221304 is an orally active, liver-targeted inhibitor of acetyl-CoA carboxylase (ACC), a rate-limiting enzymes for fatty acid synthesis.
Description | PF-05221304 is an orally active, liver-targeted inhibitor of acetyl-CoA carboxylase (ACC), a rate-limiting enzymes for fatty acid synthesis. |
In vitro | PF-05221304 blocked polarization of human T cells to proinflammatory but not anti-inflammatory T cells, and suppressed activation of primary human stellate cells to myofibroblasts in vitro, showing direct effects on inflammation and fibrogenesis[1]. |
In vivo | PF-05221304 reduced markers of inflammation and fibrosis in the diethylnitrosamine chemical-induced liver injury model and the choline-deficient, high-fat-fed rat model[1]. |
Synonyms | NSC 170984, Clesacostat, R 6238,, STAT5 Inhibitor III |
Molecular Weight | 502.571 |
Formula | C28H30N4O5 |
CAS No. | 1370448-25-1 |
Powder: -20°C for 3 years
In solvent: -80°C for 2 years
DMSO: 95mg/ml(189.03mM)
ethanol: 5mg/ml(9.95mM)
( < 1 mg/ml refers to the product slightly soluble or insoluble )
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
PF-05221304 1370448-25-1 代谢 Acetyl-CoA Carboxylase STAT5 Inhibitor III R 6238, PF 05221304 PF05221304 Clesacostat NSC 170984 Inhibitor inhibitor inhibit